VESALIUS-CV
Evolocumab vs Placebo in Patients With Atherosclerosis or Diabetes Without Prior MI or Stroke
Presented by Nicholas Marston — TIMI Study Group, Brigham and Women's Hospital
Subspecialty: Lipid / Prevention
Published in JAMA
Key Result
Evolocumab reduced 3-point MACE by 25% vs placebo in patients with ASCVD or diabetes but no prior MI/stroke (first demonstration of PCSK9 inhibitor benefit in primary prevention). Heart attack risk reduced 36%. LDL-C reduced 55% to median 45 mg/dL.
What did this trial find?
The VESALIUS-CV trial randomized 12,257 patients with atherosclerosis or diabetes but no prior MI/stroke to evolocumab or placebo, showing a 25% reduction in 3-point MACE and 36% reduction in MI over a median 4.6-year follow-up. This is the first demonstration of PCSK9 inhibitor benefit in primary prevention. The trial generated strong supportive reactions from experts, with an accompanying NEJM editorial calling it "an important step forward," though editorialists raised questions about cost-effectiveness and applicability to younger, lower-risk patients. A subsequent subgroup analysis at ACC 2026 showed a 31% MACE reduction in diabetic patients without significant atherosclerosis.
Why does this trial matter?
Mostly straightforward, highly supportive coverage. The trial is widely viewed as practice-changing, extending PCSK9 inhibitor evidence to primary prevention. The only meaningful counterpoint comes from editorialists (Greenland/Lloyd-Jones in JAMA, Ndumele/Blumenthal in NEJM) who raise questions about cost-effectiveness, long-term durability, and applicability to younger/lower-risk patients — but these are caveats rather than true controversy. No significant dissent about the core findings.
Study Design
Multinational, randomized, double-blind, placebo-controlled trial
Clinical Implications
First demonstration that a PCSK9 inhibitor significantly reduces cardiovascular events in primary prevention patients already on high-intensity lipid-lowering therapy. Supports expanding PCSK9 inhibitor use beyond secondary prevention to high-risk primary prevention populations with atherosclerosis or diabetes.
Abstract
The VESALIUS-CV trial was a randomized, double-blind, placebo-controlled trial evaluating evolocumab (a PCSK9 inhibitor) in 12,257 patients with atherosclerotic cardiovascular disease or diabetes but without previous myocardial infarction or stroke, all with LDL-C levels of at least 90 mg/dL. The median age was 66 years and 43% were women. At median follow-up, evolocumab reduced the risk of 3-point MACE (coronary heart disease death, MI, or ischemic stroke) by 25% compared to placebo. The risk of 4-point MACE (adding ischemia-driven arterial revascularization) was reduced by 19%. Heart attack risk alone was reduced by 36%. In the lipid substudy, evolocumab achieved a median LDL-C of 45 mg/dL at 48 weeks vs 109 mg/dL with placebo — a 55% reduction. Results were consistent across key subgroups including high-risk diabetic patients.